

1.1 moves to amend H.F. No. 17, the third engrossment, as follows:

1.2 Page 2, delete lines 1 to 6 and insert:

1.3 "Subd. 4. **Manufacturer.** "Manufacturer" has the meaning provided in section 151.01,
1.4 subdivision 14a, but does not include an entity required to be licensed solely because the
1.5 entity repackages or relabels drugs."

1.6 Page 8, line 6, delete "12-member" and insert "14-member"

1.7 Page 8, line 21, delete "and"

1.8 Page 8, line 23, delete the period and insert a semicolon

1.9 Page 8, after line 23, insert:

1.10 "(10) one member representing wholesale drug distributors; and

1.11 (11) one member representing pharmacy benefit managers."

1.12 Page 10, line 17, after "by" insert "more than 15 percent or by more than"

1.13 Page 10, delete lines 24 to 32 and insert:

1.14 "(4) generic drugs for which the WAC:

1.15 (i) is \$100 or more, after adjusting for changes in the CPI, for:

1.16 (A) a 30-day supply;

1.17 (B) a course of treatment lasting less than 30 days; or

1.18 (C) one unit of the drug if the labeling approved by the Food and Drug Administration
1.19 does not recommend a finite dosage; and

1.20 (ii) increased by 200 percent or more during the immediate preceding 12-month period,
1.21 as determined by the difference between the resulting WAC and the average WAC reported
1.22 over the preceding 12 months, after adjusting for changes in the CPI."

- 2.1 Page 11, delete lines 1 to 2
- 2.2 Page 13, delete lines 17 to 19
- 2.3 Page 13, line 20, delete "(d)" and insert "(c)"